Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry

Abstract

Individualising PRRT using renal dosimetry seems feasible and safe and leads to an increased number of cycles in the majority of patients. The trial will continue as planned.